insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

INKT · Mink Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · INKT

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$1.20M-$1.14M$1.84M$1.26M-$540.6K$1.84M$2.55M-
SG&A$1.68M-$1.85M$1.85M$1.27M-$1.16M$1.06M$1.28M-
Total Operating Expenses----------
D&A$36.1K---$50.8K---$53.8K-
Operating Income($2.88M)-($3.18M)($4.05M)($2.70M)-($1.88M)($3.07M)($3.83M)-
Interest Expense($4.0K)-($25.0K)($27.0K)($10.0K)-----
Income Tax----------
Net Income($2.74M)-($2.89M)($4.24M)($2.77M)-($1.81M)($2.70M)($3.81M)-
EPS - Basic($0.57)-($0.65)($1.06)($0.70)-($0.50)($0.70)($1.10)-
EPS - Diluted($0.57)-($0.65)($1.06)($0.70)-($0.50)($0.70)($1.10)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$9.53M$13.36M$14.28M$1.68M$3.23M$4.58M$6.33M$9.31M$5.82M$3.37M
Accounts Receivable----------
Inventory----------
Accounts Payable$3.39M$3.43M$3.69M$3.31M$2.66M$2.73M$2.36M$3.20M$3.49M$3.91M
Current Assets$10.02M$13.85M$14.53M$2.01M$3.58M$4.99M$6.58M$9.47M$6.00M$3.60M
Total Assets$10.38M$14.24M$14.96M$2.48M$4.27M$5.72M$7.37M$10.32M$6.89M$4.55M
Current Liabilities$7.29M$13.03M$13.43M$13.16M$12.12M$6.96M$7.40M$10.15M$11.11M$11.40M
Long-term Debt----------
Total Liabilities----------
Stockholders' Equity($12.69M)($14.23M)($13.51M)($25.19M)($21.79M)($19.59M)($17.55M)($16.58M)($20.30M)($18.06M)
Retained Earnings($159.42M)($156.68M)($154.07M)($151.19M)($146.95M)($144.18M)($141.72M)($139.91M)($137.21M)($133.40M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.73M)---($1.34M)---($2.54M)-
Investing Cash Flow----------
Financing Cash Flow($2.10M)---$576---$5.01M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-26.4%--19.3%-170.6%-64.8%--24.5%-26.2%-55.3%-
Return on equity21.6%-21.4%16.8%12.7%-10.3%16.3%18.8%-
Return on invested capital----------
Liquidity
Current ratio1.381.061.080.150.300.720.890.930.540.32
Quick ratio1.381.061.080.150.300.720.890.930.540.32
Cash ratio1.311.031.060.130.270.660.860.920.520.30
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage720.4x-127.3x150.1x270.1x-----
Equity multiplier-0.82-1.00-1.11-0.10-0.20-0.29-0.42-0.62-0.34-0.25
Liabilities / Assets----------
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-6.7%--68.9%-32.0%29.5%-63.9%51.6%34.6%-
Net income growth (YoY)0.9%--59.8%-56.8%27.4%-64.7%56.4%32.9%-
EPS growth (YoY)18.6%--30.0%-51.4%36.4%--233.3%-288.9%-547.1%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)41.8%27.4%23.0%-52.0%-7.4%-8.5%-29.3%-74.6%-353.5%-4399.2%

Peer comparison

Same SIC group: Biological Products, (No Diagnostic Substances)

CompanyRevenue (last FY)Net marginROE
TWST---16.4%
AMGN$36.75B21.0%89.1%
RXRX$74.68M-863.4%-57.0%
MRNA$1.94B-145.2%-32.6%
DNA$170.16M-183.8%-61.5%

Comparing MiNK Therapeutics against the 5 most active filers in the same SIC group.